PA8480001A1 - 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas - Google Patents
1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onasInfo
- Publication number
- PA8480001A1 PA8480001A1 PA19998480001A PA8480001A PA8480001A1 PA 8480001 A1 PA8480001 A1 PA 8480001A1 PA 19998480001 A PA19998480001 A PA 19998480001A PA 8480001 A PA8480001 A PA 8480001A PA 8480001 A1 PA8480001 A1 PA 8480001A1
- Authority
- PA
- Panama
- Prior art keywords
- aryl
- inflatory
- psoriasis
- naphtiridin
- onas
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000004681 Psoriasis Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000241 respiratory effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 240000006409 Acacia auriculiformis Species 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000000552 rheumatic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
UN COMPUESTO DE LA FORMULA I O LA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE R1, R2 Y R3 SON COMO SE HAN DEFINIDO ANTERIORMENTE, UTIL EN EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS, ALERGICOS, REUMATOIDES, DE REGULACION DEL PESO CORPORAL, INFLAMATORIOS Y DEL SISTEMA NERVIOSO CENTRAL, TALES COMO ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, SÍNDROME DE ENFERMEDADES RESPIRATORIAS EN ADULTOS, CHOQUE TOXICO, FIBROSIS, HIPERSENSIBILIDAD PULMONAR, RINITIS ALERGICA, DERMATITIS ATOPICA, PSORIASIS, CONTROL DE PESO, ARTRITIS REUMATOIDE, CAQUEXIA, ENFERMEDAD DE CROHN, COLITIS ULCEROSA, AFECCIONES ARTRITICAS Y OTRAS ENFERMEDADES INFLAMATORIAS, DEPRESIÓN, DEMENCIA MULTIINFARTO Y SIDA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9617698P | 1998-08-11 | 1998-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8480001A1 true PA8480001A1 (es) | 2000-09-29 |
Family
ID=22256080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA19998480001A PA8480001A1 (es) | 1998-08-11 | 1999-08-10 | 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas |
Country Status (44)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815951B2 (en) | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
| WO2002045749A2 (en) * | 2000-11-02 | 2002-06-13 | Research Foundation Of City University Of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| AU2003220170B2 (en) | 2002-03-15 | 2008-12-11 | Merck Sharp & Dohme Corp. | N-(Substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as HIV integrase inhibitors |
| KR100454750B1 (ko) * | 2002-06-20 | 2004-11-03 | 삼성에스디아이 주식회사 | 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자 |
| CA2506949A1 (en) * | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE10349497A1 (de) * | 2003-10-23 | 2005-05-25 | Bayer Cropscience Ag | N-substituierte Pyrazolylcarboxanilide |
| DE102004002557A1 (de) * | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
| EP1708715A1 (de) * | 2004-01-17 | 2006-10-11 | Boehringer Ingelheim International GmbH | Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| EP1915155A1 (en) * | 2005-08-03 | 2008-04-30 | Boehringer Ingelheim International GmbH | Dihydropteridinones in the treatment of respiratory diseases |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| EP2185559A1 (en) * | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| RU2654216C2 (ru) * | 2012-08-08 | 2018-05-17 | Мерк Патент Гмбх | Производные (аза-)изохинолинона |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU165405B (es) * | 1972-06-29 | 1974-08-28 | ||
| US3856800A (en) * | 1973-02-26 | 1974-12-24 | Sterling Drug Inc | Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates |
| US3882132A (en) * | 1973-03-08 | 1975-05-06 | Sterling Drug Inc | Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs |
| AU3265695A (en) * | 1994-08-29 | 1996-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Novel naphthyridine derivative and medicinal composition thereof |
| JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
-
1999
- 1999-08-05 IL IL14086899A patent/IL140868A0/xx unknown
- 1999-08-05 WO PCT/IB1999/001390 patent/WO2000009504A1/en not_active Ceased
- 1999-08-05 DK DK99933078T patent/DK1104420T3/da active
- 1999-08-05 AU AU49249/99A patent/AU4924999A/en not_active Abandoned
- 1999-08-05 CN CN99809505A patent/CN1312810A/zh active Pending
- 1999-08-05 SK SK182-2001A patent/SK1822001A3/sk unknown
- 1999-08-05 ID IDW20010315A patent/ID27843A/id unknown
- 1999-08-05 DE DE69904602T patent/DE69904602T2/de not_active Expired - Fee Related
- 1999-08-05 ES ES99933078T patent/ES2188194T3/es not_active Expired - Lifetime
- 1999-08-05 HK HK02100400.2A patent/HK1038917A1/zh unknown
- 1999-08-05 EP EP99933078A patent/EP1104420B1/en not_active Expired - Lifetime
- 1999-08-05 OA OA1200100032A patent/OA11591A/en unknown
- 1999-08-05 EA EA200100124A patent/EA200100124A1/ru unknown
- 1999-08-05 CA CA002340180A patent/CA2340180A1/en not_active Abandoned
- 1999-08-05 AP APAP/P/2001/002068A patent/AP2001002068A0/en unknown
- 1999-08-05 PT PT99933078T patent/PT1104420E/pt unknown
- 1999-08-05 KR KR1020017001718A patent/KR20010072368A/ko not_active Ceased
- 1999-08-05 HR HR20010107A patent/HRP20010107A2/hr not_active Application Discontinuation
- 1999-08-05 TR TR2001/00433T patent/TR200100433T2/xx unknown
- 1999-08-05 JP JP2000564956A patent/JP2002522541A/ja active Pending
- 1999-08-05 HU HU0103466A patent/HUP0103466A3/hu unknown
- 1999-08-05 BR BR9912902-7A patent/BR9912902A/pt not_active Application Discontinuation
- 1999-08-05 AT AT99933078T patent/ATE229955T1/de not_active IP Right Cessation
- 1999-08-05 EE EEP200100085A patent/EE200100085A/xx unknown
- 1999-08-05 GE GEAP19995743A patent/GEP20033029B/en unknown
- 1999-08-05 PL PL99346005A patent/PL346005A1/xx not_active Application Discontinuation
- 1999-08-05 NZ NZ509297A patent/NZ509297A/en not_active Application Discontinuation
- 1999-08-05 CZ CZ2001485A patent/CZ2001485A3/cs unknown
- 1999-08-06 TW TW088113482A patent/TW542835B/zh active
- 1999-08-09 GT GT199900128A patent/GT199900128A/es unknown
- 1999-08-09 PE PE1999000802A patent/PE20000950A1/es not_active Application Discontinuation
- 1999-08-09 HN HN1999000130A patent/HN1999000130A/es unknown
- 1999-08-10 PA PA19998480001A patent/PA8480001A1/es unknown
- 1999-08-10 SV SV1999000120A patent/SV1999000120A/es not_active Application Discontinuation
- 1999-08-10 TN TNTNSN99155A patent/TNSN99155A1/fr unknown
- 1999-08-10 DZ DZ990166A patent/DZ2866A1/xx active
- 1999-08-10 AR ARP990103992A patent/AR015557A1/es not_active Application Discontinuation
- 1999-08-10 MA MA25723A patent/MA26669A1/fr unknown
- 1999-08-11 CO CO99051075A patent/CO5130004A1/es unknown
- 1999-08-11 US US09/372,735 patent/US6174895B1/en not_active Expired - Fee Related
-
2001
- 2001-01-16 IS IS5815A patent/IS5815A/is unknown
- 2001-02-07 ZA ZA200101040A patent/ZA200101040B/en unknown
- 2001-02-09 NO NO20010684A patent/NO20010684L/no not_active Application Discontinuation
- 2001-03-09 BG BG105321A patent/BG105321A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8480001A1 (es) | 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas | |
| PA8449601A1 (es) | Derivados de nicotinamida | |
| DOP2006000210A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| ECSP055768A (es) | Derivados de azol-pirimidina condensados | |
| BR0317885A (pt) | Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa | |
| MX2009009443A (es) | Compuestos de pirimidina hidrazida como inhibidores de pgds. | |
| HRP20120708T1 (hr) | Kombinacija antikolinergika, glukokortikoida i beta2-agonista za lijeäśenje upalnih bolesti | |
| CO4180606A1 (es) | Compuestos de isoxazolina como agentes antiinflamatorios | |
| WO2012143796A3 (en) | Anti-inflammation compounds | |
| HRP20210090T1 (hr) | Farmaceutski pripravak koji sadrži nikotinsku kiselinu i/ili nikotinamid i/ili triptofan za pozitivan uticaj na crijevnu mikrobiotu | |
| AR040351A1 (es) | Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos | |
| MX2009000999A (es) | Derivados de quinuclidina como antagonistas de m3. | |
| CY1110998T1 (el) | Θεραπεια βακτηριακων ασθενειων των αναπνευστικων οργανων με τοπικη εφαρμογη φθοροκινολονων | |
| WO2007114848A3 (en) | Chemical compounds | |
| WO2008141786A3 (en) | Peptides having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases | |
| HRP20160328T1 (hr) | Tritokvalin za uporabu u liječenju cistične fibroze | |
| BR0312780A (pt) | Compostos de tiofeno-carboxamida substituìda para o tratamento de inflamação | |
| BRPI0414487A (pt) | composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo | |
| WO2007062318A3 (en) | Chemical compounds | |
| ECSP993095A (es) | 1-aril-3- arilmetil -8 -naftiridin -4 (1h)-(onas) | |
| IL180681A0 (en) | Pyridine derivatives, their preparation and use | |
| ECSP982468A (es) | Derivados de nicotinamida | |
| RU2008102656A (ru) | Введение в дыхательные пути активированного белка с при воспалительных состояниях, поражающих дыхательные пути | |
| Jung et al. | Secondary Ventilator Induced Diaphragmatic Dysfunction After Extubation | |
| JP1787037S (ja) | レールおもちゃ用仕掛け |